Colon cancer cell lines showed increased resistance to cetuximab when PTEN expression is lost or PIK3CA is mutated, and an even higher degree of resistance when any of these alterations is concurrently present with RAS/BRAF mutations [50]. This evidence concerns the gene PIK3CA and malignant colon neoplasm.